FDA issues final guidance on CMC postapproval changes for biologics
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaQuality Assurance and ControlRegulatory Intelligence/Policy